Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?

BACKGROUND: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies. Bevacizumab, targeting the VEGF receptor, is one of the primary targeted therapies that achieve better response rate and survival rate as compared to combination chemotherapy. To the bes...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sümbül, Ahmet Taner, Dişel, Umut, Sezgin, Nurzen, Sezer, Ahmet, Köse, Fatih, Beşen, Ali Ayberk, Sümbül, Zehra, Abalı, Hüseyin, Özyılkan, Özgür
Format: Artigo
Idioma:Inglês
Publicat: International Scientific Literature, Inc. 2014
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3962326/
https://ncbi.nlm.nih.gov/pubmed/24632679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.889945
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars